Celularity

Celularity Earnings Yield

The Earnings Yield of Celularity (CELU) as of Oct 16, 2026 is -251.65 %. In the previous year, Earnings Yield was -158.70 % — a change of 58.57% (lower).

Earnings Yield

-251.65 %

YoY

58.57%

Last updated:

Earnings Yield of Celularity is 2025 -251.65 % . Earnings Yield of Celularity was 2024 -158.70 % . It decreases by 58.57% lower compared to the previous year.

The Celularity Earnings Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Earnings Yield
Date
Earnings Yield
Jan 1, 2018
-0.00 USD
Jan 1, 2019
-580.82 USD
Jan 1, 2020
-570.82 USD
Jan 1, 2021
-274.45 USD
Jan 1, 2022
38.90 USD
Jan 1, 2023
-538.09 USD
Jan 1, 2024
-158.70 USD
Jan 1, 2025
-251.65 USD
The Celularity Earnings Yield history
YEAREarnings YieldYoY
-251.65 %+58.57%
-158.70 %-70.51%
-538.09 %-1,483.14%
38.90 %-114.18%
-274.45 %-51.92%
-570.82 %-1.72%
-580.82 %+19.30 M%
-0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celularity Stock analysis

What does Celularity do? Celularity Inc, listed on the stock market with ticker CELU and ISIN US1511902041, is a biotechnology company headquartered in Florham Park, New Jersey, United States. The company operates within the Health Care sector, specifically in the Biotechnology industry. Celularity has 225 employees and completed its initial public offering (IPO) on May 23, 2019. The company focuses on developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune disorders, and infectious diseases. Its research and development efforts include various therapy product candidates such as T cells engineered with a chimeric antigen receptor (CAR), natural killer cells, mesenchymal-like adherent stromal cells (MLASCs), and exosomes. These therapeutic candidates target a range of conditions including cancer, infectious diseases, and degenerative diseases. Celularity's product pipeline features several programs, including CYCART-19, which is a placental-derived CAR-T cell therapy targeting B-cell malignancies, and pEXO-001, among others. The company's operations are structured around three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Celularity's website is https://celularity.com/. Celularity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celularity stock

Earnings Yield of Celularity is -251.65 % in 2025.

Earnings Yield of Celularity changed from -158.70 % to -251.65 %, representing a 58.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings Yield Celularity since 2006 – with annual values, charts, and detailed analysis.

Earnings Yield is the inverse of the P/E ratio. It shows the percentage of each dollar invested that was earned by the company. Higher earnings yield indicates better value.

To evaluate Earnings Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Earnings Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Earnings Yield's Celularity with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Celularity

All Key Metrics — Celularity